Simons F E
Section of Allergy and Clinical Immunology, Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Canada.
Can Respir J. 1999 Mar-Apr;6(2):175-8. doi: 10.1155/1999/957127.
In children with persistent asthma, inhaled glucocorticoids decrease symptoms and exacerbations, decrease the need for rescue bronchodilator medications, improve airway patency and reduce airway hyperresponsiveness. When administered in the lowest doses that prevent symptoms and eliminate the need for supplemental courses of oral glucocorticoids, they are unlikely to cause clinically important systemic adverse events. Inhaled glucocorticoids have a favourable risk to benefit ratio in this population.
在持续性哮喘患儿中，吸入性糖皮质激素可减轻症状和病情加重，减少急救支气管扩张剂药物的使用需求，改善气道通畅性并降低气道高反应性。当以预防症状并消除口服糖皮质激素补充疗程需求的最低剂量给药时，它们不太可能引起具有临床重要意义的全身性不良事件。吸入性糖皮质激素在该人群中具有良好的风险效益比。
